Foundation Medicine and Natera FoundationOne Tracker

Foundation Medicine and Natera have launch the research use version of FoundationOne Tracker, Foundation Medicine’s personalized circulating tumor DNA monitoring assay. FoundationOne Tracker combines Foundation Medicine's tissue-based comprehensive genomic profiling platform with Natera's expertise in ctDNA monitoring.

The assay uses optimized algorithms to identify tumor-specific variants and a personalized design to detect ctDNA in plasma, and is meant for use in both advanced- and early-stage research applications. Additionally, the fully integrated workflow between Foundation Medicine and Natera is expected to provide rapid inclusion of ctDNA monitoring results into retrospective research studies, the companies said.